Form 13G Filing by Squarepoint Entities for Cartesian Therapeutics, Inc.

This filing details the beneficial ownership of Cartesian Therapeutics, Inc. common stock by several Squarepoint entities. Squarepoint Ops LLC, Squarepoint Capital LLP, Squarepoint Operations Private Limited, and Squarepoint (DIFC) Limited each hold 8.34% of the outstanding shares, amounting to 2,209,601 shares. Additionally, Squarepoint Master Fund Limited holds 8.22% (2,178,652 shares), and Squarepoint Core Master Fund Limited holds 0.12% (30,949 shares). The filing confirms that these securities were not acquired or held for the purpose of influencing the control of the issuer. The reporting individuals are John Weitzer, Chief Compliance Officer for all reporting entities. The filing date is March 13, 2026.